Recently, three peptide epitopes, KSFKDILPK (SAG1 224-232 ), AMLTAFFLR (GRA6 164-172 ), and RSFKD LLKK (GRA7 134-142 ), were found by our group to elicit IFN-γ from peripheral blood mononuclear leukocytes (PBMCs) from T. gondii seropositive HLA-A03 supertype humans but not from PBMCs of T. gondii seronegative HLA-A03 supertype humans [18] . Herein, initially we designed 4 CD8 + T cell epitope containing vaccine formulations comprised of lipopeptides that incorporate PADRE as well as a novel oil-in-water emulsion that includes a specially formulated synthetic MLA derivative called GLA-SE [21] [22] [23] [24] . First, efficacy of various vaccine formulations consisting of the three previously identified CD8 + T cell peptides eliciting HLA-A*1101-restricted, CD8 + T cell-mediated IFN-γ production in vitro from HLA-A*1101 mice was examined.